Drug Trial Radar · NCT05419180
Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Oct 13, 2022
Primary completion
Jun 13, 2024
Study completion Jun 13, 2024
Sponsor
- Lead sponsor
- BiocodexIndustry
- Sponsor type
- Industry
- First posted
- Jun 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.
Conditions
- Pharmacoresistant Focal Epilepsies
Interventions
StiripentolDrug
Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AgeTime frame: through study completion, an average of 1 year
- Previous antiepileptic treatments receivedTime frame: through study completion, an average of 1 year
- SurgeryTime frame: through study completion, an average of 1 year
- Adjustment of carbamazepine treatment over the timeTime frame: through study completion, an average of 1 year
- Adjustment of stiripentol treatment over the timeTime frame: through study completion, an average of 1 year
- Adjustment of concomitant treatments over the timeTime frame: through study completion, an average of 1 year
- monthly seizures over the timeTime frame: through study completion, an average of 1 year
- status epilepticus in the pastTime frame: through study completion, an average of 1 year
- duration of the status epileticus over the timeTime frame: through study completion, an average of 1 year
- emergency room consultation and/or hospitalization over the timeTime frame: through study completion, an average of 1 year
- emergency antiepileptic treatment over the timeTime frame: through study completion, an average of 1 year
- frequency of the status epileticus over the timeTime frame: through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre de Référence Epilepsies Rares / Centre Investigation Clinique (CIC) - Hôpital Necker-Enfants Malades
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.